ASTANA, Kazakhstan, April 15. The Egyptian EIPICO plans to build a full-cycle biopharmaceutical plant in the Karaganda region of Kazakhstan, Trend reports.
This topic was discussed during a meeting between Madina Abdikadyr, the Project Manager of KAZAKH INVEST (Kazakhstan's national company), and Ahmad Kilani, the Chairman of the Board of Directors of EIPICO.
The parties noted that implementation of the project for the production of biosimilars and anticancer drugs in accordance with international GMP standards will lead to the creation of 150–200 permanent jobs. Products for the treatment of oncologic diseases will be supplied to the local and nearby markets.
The planned investment volume for the project will be $30 million.
Madina Abdikadyr assured Egyptian investors of her full support, noting that previously there was no full-cycle pharmaceutical production in Kazakhstan.
EIPICO is Egypt's largest pharmaceutical manufacturer, with 276 medicines in 25 therapeutic groups. The company's products are the leader in the Egyptian market, accounting for 21 percent of the country's total pharmaceutical exports.
Meanwhile, the volume of trade turnover between Kazakhstan and Egypt in 2023 amounted to $161.2 million. The structure of trade turnover is dominated by imports from Egypt, worth $137.5 million. Kazakh exports to Egypt for the above period amounted to $23.6 million.